ctDNA shows promise for monitoring paediatric gliomaDecember 13, 2018
Panditharatna E. et al shows early evidence in proper monitoring of paediatric diffuse midline gliomas (DMGs) using liquid biopsy. The researchers indicate the study to be the first to focus on the clinical utility of circulating tumour DNA (ctDNA) for longitudinal surveillance of DMGs in children. The assay quantified the levels of a mutation, H3K27M, which is known to be present in over 70 percent of patients with DMG correlating with a poorer clinical outcome. The study reported the identification of H3K27M in pre-treatment samples from 42 of the 48 patients, a frequency that is comparable to what is seen in tissue samples showing cerebral spinal fluid to exhibit the presence of more mutated DNA, overall, than blood. Researchers observed a significant decrease in ctDNA in a subset of children with Diffuse Intrinsic Pontine Glioma (DIPG) who had liquid biopsy testing before and after radiation treatment in a clinical trial. Researchers also reported an agreement of 75 percent between ctDNA response (a 50 percent decrease or more) and MRI tumour volume measurements (at least 10 percent decrease). The liquid biopsy approach thus provides a molecularly based tool for tumour characterization helping doctors to monitor how well treatments are working in children with DMGs.
Source: American Association for Cancer Research, October 15, 2018/ DOI: 10.1158/1078-0432.CCR-18-1345 /